ProPhase Labs, Inc.: Form 10-K for the period ended Dec 31, 2011
Filed with the SEC on Mar 7, 2012 and accepted by EDGAR at Mar 7, 2012, 15:43 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2011-01-01 to 2011-12-31 | $17.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months2011-01-01 to 2011-12-31 | $6.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2011-01-01 to 2011-12-31 | $11.3m | us-gaap:GrossProfit |
| Research and development | 12 months2011-01-01 to 2011-12-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2011-01-01 to 2011-12-31 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2011-01-01 to 2011-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2011-01-01 to 2011-12-31 | −$2.7m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2011-01-01 to 2011-12-31 | −$2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2011-01-01 to 2011-12-31 | $300.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-12-31 | $5.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-12-31 | $13.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-12-31 | $19.1m | us-gaap:Assets |
| Current liabilities | At period end2011-12-31 | $7.9m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2011-12-31 | $11.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-12-013420. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.